How to Qualify for a GLP-1 for Weight Management

The short answer

The two GLP-1 medications FDA-approved specifically for chronic weight management are Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide). Their diabetes-approved cousins, Ozempic (semaglutide) and Mounjaro (tirzepatide), are approved to treat type 2 diabetes; prescribing either for weight loss alone is off-label. That distinction changes what you qualify for, how insurance treats the claim, and what the label warns about.

This page walks through the exact eligibility criteria, what a prescriber assesses during the visit, the contraindications printed on the labels, how insurance prior authorization works, the real cost structure, and the legal telehealth route to a prescription. It is written for women weighing menopause-era weight changes and hormonal factors, but the qualification rules apply to any adult. This site does not sell or prescribe medication; it helps you compare providers licensed in your state.

The FDA BMI criteria, in plain numbers

The eligibility bar is written into the label itself. The Wegovy prescribing information indicates the drug as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition. The Zepbound prescribing information carries essentially the same two-tier threshold. This is why the very first data point in any qualification visit is your height and weight.

BMI is weight in kilograms divided by height in meters squared. At 5 feet 4 inches, a BMI of 30 corresponds to roughly 175 pounds, and a BMI of 27 corresponds to roughly 157 pounds. Those figures are illustrative arithmetic from the BMI formula, not a promise about any individual case, because BMI does not measure body composition and a clinician interprets it alongside your overall health.

The practical takeaway: if your BMI is 30 or above, you meet the weight threshold on its own. If your BMI is between 27 and 29.9, you also need a documented weight-related condition to qualify under the label. Below 27, you do not meet the FDA label criteria for these weight-management drugs, and a responsible prescriber will not write the prescription.

Eligibility at a glance

The table below summarizes how BMI and comorbidity interact to determine label eligibility for the weight-management GLP-1 drugs. It reflects the Indications sections of the Wegovy and Zepbound labels and is a screening guide, not a substitute for a clinician's judgment.

Two thresholds do all the work here: BMI 30 stands on its own, while the 27-to-29.9 band only qualifies when paired with a documented weight-related condition. Anything below 27 falls outside the label for these drugs.

What counts as a weight-related comorbid condition

For people in the 27 to 29.9 BMI band, qualification hinges on having a documented weight-related condition. The labels name examples including hypertension (high blood pressure), type 2 diabetes mellitus, and dyslipidemia (abnormal blood lipids such as high cholesterol or triglycerides). Obstructive sleep apnea and cardiovascular disease are other conditions clinicians commonly weigh in this context.

These are conditions a prescriber can verify from your chart, a blood pressure reading, or lab work, not something you can self-declare in a two-minute form. If you believe you qualify on this basis, bring records: a recent lipid panel, blood pressure logs, or an existing diagnosis code. Documentation is also what an insurer's prior-authorization reviewer looks for.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) frames obesity as a chronic disease and describes prescription weight-management medications as tools used alongside lifestyle changes, not replacements for them. That framing matters because the label itself positions these drugs as an adjunct to reduced-calorie diet and increased physical activity.

Weight-approved vs diabetes-approved: why the drug name matters

Semaglutide and tirzepatide each exist under two brand names with different FDA-approved uses. Wegovy is semaglutide approved for chronic weight management; Ozempic is the same molecule approved for type 2 diabetes. Zepbound is tirzepatide approved for chronic weight management; Mounjaro is the same molecule approved for type 2 diabetes. You can confirm any product's approved status in the FDA's Drugs@FDA database.

If you do not have diabetes and want a GLP-1 for weight, the on-label choices are Wegovy or Zepbound. A prescriber can legally prescribe Ozempic or Mounjaro off-label for weight, but that is off-label use, and insurers routinely deny weight-loss claims for the diabetes-branded products because the FDA-approved indication is diabetes. Knowing which brand matches your goal saves you a denied prior authorization.

This also affects supply and savings programs. Each manufacturer runs a separate coverage and savings page for each brand, and the terms differ. The weight brands and the diabetes brands are not interchangeable at the pharmacy counter even when the active ingredient is identical.

Comparing the four GLP-1 brands

Use this table to match your situation to the right conversation with a prescriber. Approved uses are taken from each drug's FDA prescribing information.

The pattern to notice: the same two molecules appear twice each, and only the weight-branded versions are on-label when weight loss is the goal and you do not have diabetes.

What a prescriber actually assesses

A qualification visit is more than a BMI calculation. A clinician reviews your weight history and prior attempts at diet and activity, your current medications, and your personal and family medical history, specifically screening for the contraindications listed on the label. They will ask about thyroid cancer history, pregnancy status or plans, pancreatitis, gallbladder disease, and gastrointestinal conditions, because these shape whether a GLP-1 is safe for you.

Expect questions about other medicines you take, since GLP-1 drugs slow stomach emptying and can affect how oral medications are absorbed. For women, this includes birth control pills, thyroid medication, and menopause hormone therapy. The prescriber is deciding not only whether you qualify, but which drug and what starting dose fits your history.

A legitimate telehealth prescriber follows the same logic as an in-person one: eligibility check, contraindication screen, medication review, and a plan for follow-up and dose titration. If an online service skips the medical history and offers to ship a GLP-1 after a one-line questionnaire, that is a signal to walk away.

Contraindications the label rules out

The prescribing information for these drugs lists specific situations where the drug should not be used. Both semaglutide and tirzepatide labels carry a boxed warning about thyroid C-cell tumors based on rodent studies, and they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If either applies to you or a close relative, you will not qualify for these medications.

The labels also contraindicate use in patients with a known serious hypersensitivity to the active ingredient or any of the product's components. A prior severe allergic reaction to semaglutide or tirzepatide rules out that drug.

Pregnancy is a critical screen. These weight-management drugs are not recommended in pregnancy, and weight loss offers no benefit to a developing pregnancy. Because tirzepatide can reduce oral contraceptive effectiveness, women of reproductive age need a reliable contraception plan discussed at the qualifying visit, not as an afterthought.

Women-specific factors: menopause, contraception, and hormones

Weight gain and shifting body composition are common concerns around perimenopause and menopause, and many women ask about GLP-1 drugs in that window. The eligibility rules do not change with menopause: the same BMI 30, or 27-with-a-condition, threshold applies. What changes is the surrounding medication picture a prescriber must account for.

The tirzepatide labels (Zepbound and Mounjaro) warn that the drug may reduce the effectiveness of oral contraceptives and advise measures such as switching to a non-oral contraceptive or adding a barrier method around the start and dose increases. Semaglutide (Wegovy, Ozempic) does not carry that specific contraceptive warning. If you rely on the pill, that difference is worth raising directly with your prescriber.

Menopause hormone therapy is a separate decision from GLP-1 eligibility, and the two are not substitutes for each other. The American College of Obstetricians and Gynecologists provides patient guidance on hormone therapy for menopause. For what estradiol and other menopause hormone therapies cost, see our own how-much-does pricing pages rather than any figure invented here.

How insurance prior authorization works

Even when you meet the FDA label criteria, coverage is a separate hurdle. Many commercial plans and Medicare Part D historically excluded drugs used for weight loss, so the first question is whether your specific plan covers the weight indication at all. Read your formulary or call the number on your insurance card before assuming coverage.

When a plan does cover a weight-management GLP-1, it usually requires prior authorization. Typical criteria mirror the label: documented BMI at or above 30, or at or above 27 with a qualifying comorbidity, plus sometimes evidence of prior lifestyle intervention or a documented weight-loss attempt. The prescriber's office submits this; your job is to supply accurate history and records.

If the diabetes brand is prescribed off-label for weight, expect denials, because the approved indication on file is diabetes. This is another reason the weight-approved brands (Wegovy, Zepbound) are the cleaner path when weight is the goal and you want insurance to pay.

The real cost structure, without invented numbers

What you pay depends entirely on which lane you are in, and the honest answer is a structure, not a single price. The list price is the manufacturer's published price before any insurance or discount. An insured copay is what your plan leaves you owing after coverage, which varies by formulary tier. A manufacturer savings card can lower out-of-pocket cost for eligible, commercially insured patients under that program's terms. A cash or self-pay price applies when insurance does not cover the drug. Compounded versions sit outside all of this and outside FDA approval.

For a current, specific dollar figure, go to the source for your drug: Lilly's Zepbound coverage and savings page, Novo Nordisk's Save on Wegovy page, and the NovoCare cost and coverage pages. Those manufacturer pages are the only place a live price should come from, and prices and savings-card terms change, so check them at the moment you are deciding rather than trusting a number quoted elsewhere.

Be wary of any third party quoting a precise pharmacy price, a GoodRx figure, or a tidy average as if it were fixed. Real out-of-pocket cost is individual to your plan and the current savings-card rules, which is exactly why the manufacturer page is the reference point.

Cost lanes compared

This table describes the cost lanes conceptually so you know which one you are in and where to get the live number. It intentionally contains no dollar figures, because the only reliable source for those is the manufacturer's own page at the moment you check.

Identify your lane first, then chase the number from the correct source: your plan's formulary for a copay, the drug's official savings page for card terms, and the manufacturer self-pay program for cash pricing.

The legal path to a prescription

A GLP-1 is a prescription medication; there is no legal way to buy Wegovy, Zepbound, Ozempic, or Mounjaro without a prescription. The legitimate route, whether in person or by telehealth, is the same three steps: an eligibility and medical assessment by a licensed prescriber, a prescription written when it is appropriate for you, and dispensing by a licensed pharmacy.

A proper telehealth service collects a real medical history, screens for the label contraindications, verifies your identity and location so a clinician licensed in your state can treat you, and arranges follow-up for dose titration and side-effect monitoring. Compare providers on whether they do these things, not on who promises the fastest shipment.

This site is affiliate-only and does not sell or prescribe medication. When you are ready, the useful next step is to compare providers licensed in your state and confirm they follow this assessment-first process.

How to prepare for a qualifying visit

Walk in with the information a prescriber needs to confirm eligibility in one visit. Know your current height and weight so BMI can be calculated, and bring documentation of any weight-related condition, such as a recent blood pressure log, a lipid panel, or an existing diagnosis, if you are relying on the 27-plus-comorbidity path.

List every medication and supplement you take, including birth control, thyroid medication, and any menopause hormone therapy, because these interact with how GLP-1 drugs are dosed and absorbed. Be ready to answer questions about personal and family history of thyroid cancer or MEN 2, pancreatitis, gallbladder disease, and pregnancy status or plans.

Finally, decide your goal before the visit. If weight is the target and you want insurance to consider coverage, the on-label brands Wegovy and Zepbound are the direct request. If you also have type 2 diabetes, that changes the conversation and may open the diabetes-approved options on-label.

Frequently asked questions

What BMI do I need to qualify for a GLP-1 for weight loss?

Under the Wegovy and Zepbound FDA labels, you qualify with a BMI of 30 or higher, or a BMI of 27 or higher if you also have at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Below a BMI of 27 you do not meet the label criteria for these weight-management drugs.

Can I get Ozempic or Mounjaro just for weight loss?

Ozempic and Mounjaro are FDA-approved for type 2 diabetes, so prescribing either for weight alone is off-label. A clinician can legally do it, but insurers commonly deny weight-loss claims for the diabetes brands. If weight is your goal, the on-label options are Wegovy and Zepbound.

What conditions would disqualify me from a GLP-1?

The labels contraindicate these drugs in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in anyone with a known serious hypersensitivity to the drug. Pregnancy is also a reason not to use them. A prescriber screens for all of these before writing a prescription.

Does a GLP-1 affect birth control?

The tirzepatide labels for Zepbound and Mounjaro warn that the drug may reduce the effectiveness of oral contraceptives and advise a non-oral method or an added barrier method around starting and dose increases. Semaglutide (Wegovy, Ozempic) does not carry that specific warning. Discuss your contraception with your prescriber.

Will insurance cover a GLP-1 for weight management?

It depends on your plan. Many plans have excluded weight-loss drugs, so check your formulary first. When covered, plans usually require prior authorization documenting your BMI, a covered indication, and sometimes prior lifestyle attempts. Off-label use of a diabetes brand for weight is frequently denied.

How much does a GLP-1 cost?

Cost depends on your lane: manufacturer list price, insured copay, savings-card price, cash self-pay, or compounded. For a current figure, check the drug's official manufacturer savings and coverage page (such as Lilly's Zepbound page or Novo Nordisk's Wegovy page), since prices and savings terms change. Avoid third-party quotes presented as fixed prices.

Are compounded semaglutide and tirzepatide a legitimate way to qualify cheaply?

Compounded semaglutide and tirzepatide are not FDA-approved products, and the FDA has warned about unapproved and compounded GLP-1 products. Their availability shifted with the drugs' shortage status. Treat them as outside the approved supply chain and verify any product in the FDA's Drugs@FDA database.

Can I buy a GLP-1 online without a prescription?

No. These are prescription medications, and there is no legal way to obtain them without a prescription. The legitimate path is an assessment by a licensed prescriber, a prescription when appropriate, and dispensing by a licensed pharmacy. Sellers offering the drug with no medical assessment are a warning sign.

Primary sources

1. FDA Prescribing Information, Zepbound (tirzepatide) injection
2. FDA Prescribing Information, Wegovy (semaglutide) injection
3. FDA Prescribing Information, Mounjaro (tirzepatide) injection
4. FDA Prescribing Information, Ozempic (semaglutide) injection
5. FDA Drugs@FDA approved-drug database
6. NIDDK (NIH), Prescription Medications to Treat Overweight & Obesity
7. Lilly, Zepbound coverage & savings
8. Novo Nordisk, Save on Wegovy
9. NovoCare, Wegovy cost & coverage
10. ACOG, Hormone Therapy for Menopause (patient FAQ)